Drotaverine, tablets 40 mg, 50 pcs.

Pharmacological action – myotropic, antispasmodic, vasodilator.

The chemical structure and pharmacological properties are similar to papaverine, but the effect is stronger and more prolonged. It reduces influx of calcium ions into smooth muscle cells (inhibits phosphodiesterase, leads to accumulation of intracellular cAMP).

It reduces tone of smooth muscles of internal organs and intestinal peristalsis, dilates blood vessels. It does not affect the autonomic nervous system and does not penetrate to the central nervous system.

The direct effect on the smooth muscles allows it to be used as an antispasmodic when drugs from the group of M-cholinoblockers are contraindicated (closed-angle glaucoma, prostatic hyperplasia).

Pharmacokinetics

In oral administration the absorption is high, half-absorption period is 12 minutes. Bioavailability – 100%. It is evenly distributed in the tissues, penetrates into the smooth muscle cells.

The time of reaching maximum concentration in the blood is 2 hours. Binding with plasma proteins is 95-98%. It is mainly excreted by kidneys, to a lesser extent – with bile.

It doesn’t penetrate through the blood-brain barrier.

Indications

Active ingredient

Composition

1 tablet contains:
active ingredient: 40 mg drotaverine hydrochloride.
excipients: potato starch, lactose, polyvinyl-pyrrolidone (povidone), talc, magnesium stearate.

How to take, the dosage

Adults are prescribed orally 40-80 mg (1-2 tablets) 2 to 3 times a day.

Children under 6 years of age are prescribed a single dose of 10-20 mg (1/4-1/2 tablets), from 6 to 12 years – 20 mg (1/2 tablet) 1-2 times a day.

Younger children are prescribed a single dose of 10-20 mg (1/4-1/2 tablets).

Interaction

Concomitant use may weaken the anti-Parkinsonian effect of levodopa.

Enhances the effects of papaverine, bendazole and other antispasmodics (including M-cholinoblockers), reduction of blood pressure caused by tricyclic antidepressants, quinidine and procainamide.

Decreases the antispasmodic activity of morphine.

Phenobarbital increases the spasmolytic effect of drotaverine hydrochloride.

Special Instructions

At the time of treatment, it is necessary to refrain from driving and engaging in potentially dangerous activities that require high concentration and quick psychomotor reactions.

Contraindications

With caution – expressed atherosclerosis of coronary arteries, prostatic hyperplasia, closed-angle glaucoma, pregnancy and lactation.

Side effects

Central nervous system disorders: infrequent – dizziness.

Cardiovascular system disorders: infrequent – palpitations, decreased blood pressure.

Feeling of fever, sweating.

Allergic skin reactions.

Overdose

Concomitant use may weaken the anti-Parkinsonian effect of levodopa.

Enhances the effects of papaverine, bendazole and other antispasmodics (including M-cholinoblockers), reduction of blood pressure caused by tricyclic antidepressants, quinidine and procainamide.

Decreases the antispasmodic activity of morphine.

Phenobarbital increases the spasmolytic effect of drotaverine hydrochloride.

In high doses it disrupts atrial-ventricular conduction, reduces excitability of the heart muscle, may cause cardiac arrest and paralysis of the respiratory center.

Similarities